Electrocautery vs Q-switch for Seborrheic Keratosis

Comparing the Efficacy and Risk of Adverse Events of Electrocautery Versus 532 nm Qswitched Neodymium-doped Yttrium Aluminium Garnet Laser for the Treatment of Flat Seborrheic Keratoses: A Randomized Control Trial

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02366559

Enrollment

Registered

2015-02-19

Start date

2015-08-31

Completion date

2016-12-31

Last updated

2021-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Keratosis, Seborrheic

Brief summary

The primary objective of this study is to compare the efficacy and risk of adverse events of electrocautery versus 532 nm Q-switched neodymium-doped yttrium aluminium garnet (Nd:YAG) laser for the treatment of flat seborrheic keratoses. This study is a pilot study designed to determine feasibility of these procedures.

Interventions

DEVICEHyfrecator

DEVICE532 nm Q-switched Nd:YAG laser

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

1. Subjects are Caucasian or Asian. 2. Subjects who are between 18-65 year olds. 3. Subjects have flat or macular seborrheic keratosis on dorsum of the hands and wrists, extensor surfaces of the forearms. The diagnosis of flat seborrheic keratosis is confirmed by two clinical dermatologists using routine clinical examination and dermoscopy. 4. Subjects have Fitzpatrick skin type I-III. 5. Subjects are in good health. 6. Subjects have the willingness and the ability to understand and provide informed consent and communicate with the investigator.

Exclusion criteria

1. History of keloids or hypertrophic scars. 2. Pregnant or lactating or intends to become pregnant in the next 3 months. 3. Active skin disease or skin infection in the treatment area. 4. Previous history of lidocaine allergy. 5. History of methemoglobinemia 6. Unable to understand the protocol or to give informed consent. 7. Any other condition that would, in the professional opinion of the investigator, potentially affect response or participation in the clinical study or would pose as an unacceptable risk to subject.

Design outcomes

Primary

Measure	Time frame	Description
Change in Pigmentation from baseline to week 18	Baseline and 18 weeks	Blinded photo raters will the lesion pigmentation on a scale of -50 (most hypopigmented relative to baseline) to +50 (most hyperpigmented relative to baseline) for both treatments.
Change in lesion texture from baseline to week 18	Baseline and 18 weeks	Blinded photo raters will the lesion texture on a scale of -50 (most worsening relative to baseline) to +50 (most improvement relative to baseline) for both treatments.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026